Drug Profile
CTX 1
Alternative Names: CTX1Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Invenio Therapeutics
- Class Small molecules
- Mechanism of Action MDM4 protein inhibitors; Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
- 28 May 2019 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA